Clinical trial
A Study of T2000 in Essential Tremor
NCT00321087 · Sun Pharmaceutical Industries, Inc., Industry · Terminated
Key facts
| NCT number | NCT00321087 |
|---|---|
| Title | A Study of T2000 in Essential Tremor |
| Official title | Phase II Efficacy and Safety of Taro Pharmaceuticals' Pro-Drug T2000 (1,3-Dimethoxymethyl-5,5-Diphenyl-Barbituric Acid) In Patients With Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled, Sequential Dose Escalation Study |
| Lead sponsor | Sun Pharmaceutical Industries, Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Essential Tremor |
| Intervention type | Drug |
| Interventions | T2000 |
| Enrollment | 10 |
| Start date | Aug 1, 2006 |
| Primary completion | Jul 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | May 3, 2006 |
| Last update posted | Jan 22, 2014 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: